Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flumatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 18/20 | 1.00 |
| ▸ | BCR | P11274 | 15/20 | 1.00 |
| ▸ | KIT | P10721 | 5/20 | 0.95 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.95 |
| ▸ | LYN | P07948 | 7/20 | 0.81 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.66 |
| ▸ | RAD52 | P43351 | 1/20 | 0.66 |
| ▸ | CSF1R | P07333 | 3/20 | 0.62 |
| ▸ | SRC | P12931 | 2/20 | 0.61 |
| ▸ | SYK | P43405 | 2/20 | 0.61 |
| ▸ | LCK | P06239 | 2/20 | 0.61 |
| ▸ | FYN | P06241 | 2/20 | 0.61 |
| ▸ | BRAF | P15056 | 2/20 | 0.61 |
| ▸ | NQO2 | P16083 | 2/20 | 0.61 |
| ▸ | ABL2 | P42684 | 2/20 | 0.61 |
| ▸ | FRK | P42685 | 2/20 | 0.61 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.61 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flumatinib SCHEMBL29573502 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRBLYN | |
| Flumatinib SCHEMBL29572991 | 1.00 | ABL1 (1.00) | ABL1BCRKITPDGFRBLYN | |
| Flumatinib SCHEMBL30087592 | 0.97 | ABL1 (1.00) | ABL1BCRKITPDGFRBLYN | |
| Flumatinib SCHEMBL29410819 | 0.97 | ABL1 (1.00) | ABL1BCRKITPDGFRBLYN | |
| Flumatinib SCHEMBL29384719 | 0.97 | ABL1 (1.00) | ABL1BCRKITPDGFRBLYN | |
| Flumatinib SCHEMBL4883843 | 0.97 | ABL1 (1.00) | ABL1BCRKITPDGFRBLYN | |
| SCHEMBL4885468 | 0.91 | ABL1 (0.85) | ABL1BCRKITPDGFRBLYN | |
| SCHEMBL4890238 | 0.90 | ABL1 (1.00) | ABL1BCRKITPDGFRBLYN | |
| SCHEMBL3560947 | 0.89 | ABL1 (1.00) | ABL1BCRKITPDGFRBLYN | |
| SCHEMBL988244 | 0.89 | ABL1 (0.84) | ABL1BCRKITPDGFRBLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | claimed |
| CN-111072636-B | Synthesis method of flumatinib | 江苏豪森药业集团有限公司 | 2022-08-23 | — | — | CN | disclosed |
| CN-110687238-B | Detection method of flumatinib mesylate related substances | 江苏豪森药业集团有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-107663151-B | Intermediate synthesis method of flumatinib mesylate | 江苏豪森药业集团有限公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | disclosed |
| CN-111072636-A | Synthesis method of flumatinib | 江苏豪森药业集团有限公司 | 2020-04-28 | — | — | CN | disclosed |
| CN-110687238-A | Detection method of flumatinib mesylate related substances | 江苏豪森药业集团有限公司 | 2020-01-14 | — | — | CN | disclosed |
| EP-1840122-B1 | AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF | SUN PIAOYANG (CN) | 2013-08-28 | — | — | EP | disclosed |
| US-8183242-B2 | Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof | Sun, Piaoyang (CN) | 2012-05-22 | — | — | US | disclosed |
| US-20080312251-A1 | Aminopyrimidine Compounds and Their Salts, Process for Preparation and Pharmaceutical Use Thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2008-12-18 | — | — | US | disclosed |
| EP-1840122-A1 | AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF | Sun, Piaoyang (CN) | 2007-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312251-A1 | Aminopyrimidine Compounds and Their Salts, Process for Preparation and Pharmaceutical Use Thereof | DPYD, PKN2, TYMP | ABL1 7/4885BCR 2529/4885KIT 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.